CDC Revises RSV Vaccine Guidelines Over Side Effect Concerns - WebMD
Aug 7, 2024 · RSV vaccination is now recommended for all people ages 75 and older. People ages 60 to 74 who are at increased risk for severe disease due to RSV should also get …
The new RSV vaccines for older adults - Mayo Clinic Press
Sep 19, 2023 · In May 2023, pharmaceutical companies GSK and Pfizer received approval from the U.S. Food and Drug Administration (FDA) for their RSV vaccines within weeks of each …
FDA requires Guillain-Barre label warnings for 2 RSV vaccines
2 days ago · The US Food and Drug Administration (FDA) announced yesterday that it has required and approved labeling changes for two respiratory syncytial virus (RSV) vaccines …
U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults …
Oct 22, 2024 · ABRYSVO now offers the broadest RSV vaccine indication for adults, which previously included those 60 years and older. Additionally, it remains the only RSV …
FDA approves first vaccine for RSV, a moment six decades in the ... - CNN
May 3, 2023 · After a 60-year scientific quest, the world has its first vaccine to protect against respiratory syncytial virus, or RSV – and more are on the way. On Wednesday, the US Food …
CDC issues new guidelines for RSV vaccines, citing side-effect …
Aug 6, 2024 · The Centers for Disease Control and Prevention (CDC) has narrowed its recommendations for which older adults should get a vaccine against respiratory syncytial …
FDA requires Pfizer, GSK to add warning on label of RSV shots
2 days ago · During an FDA advisory panel meeting in October, the agency pointed out that each million of RSV vaccine doses administered could prevent nearly 10,000 hospitalizations in …
FDA says RSV vaccines must come with Guillain-Barré warning
2 days ago · The FDA will require RSV vaccines to carry a warning about Guillain-Barré syndrome. Federal vaccine advisors expressed concern about a potential association between …
FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine
Today, the U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use in the United States. Arexvy is approved for the …
FDA Alert: FDA Requires Guillain-Barré Syndrome (GBS) Warning …
4 days ago · Subsequently, FDA has approved the vaccine for use in individuals 50 through 59 years of age who are at increased risk for LRTD caused by RSV. RECOMMENDATION: …